This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krippl, P. Articles by Samonigg, H. Search for Related Content PubMed PubMed Citation Articles by Krippl, P. Articles by Samonigg, H.

The 5A/6A Polymorphism of the Matrix Metalloproteinase 3 Gene Promoter and Breast Cancer

¹ Department of Internal Medicine, Division of Oncology, ² Clinical Institute for Medical and Chemical Laboratory Diagnostics, and Departments of ³ Internal Medicine and ⁴ Orthopedic Surgery, Medical University Graz, Graz, Austria, and ⁵ Department of Internal Medicine, Landeskrankenanstalten Salzburg, Salzburg, Austria

Purpose: The matrix metalloproteinase 3 (MMP3), also known as stromelysin-I, is a key-player for carcinogenesis and tumor growth. A 5A/6A promoter polymorphism is associated with differences in MMP3 activity and has been linked to cancer susceptibility in some studies. In the present study we evaluated the role of this polymorphism for breast cancer risk.

Experimental Design: A case–control study was performed including 500 patients with histologically confirmed breast cancer and 500 female, age-matched, healthy control subjects from population-based screening studies. The MMP3 5A/6A polymorphism was determined by a 5'-nuclease (TaqMan) assay.

Results: Prevalences of 5A/5A, 5A/6A, and 6A/6A genotypes were similar among patients (20.6, 51.8, and 27.6%, respectively) and controls (23.3, 47.3, and 29.4%, P = 0.34). The odds ratio of carriers of a MMP3 5A allele for breast cancer was 1.09 (95% confidence interval, 0.83–1.44). Patients with the 5A/5A genotype had a higher proportion of lymph-node metastases than those with a 5A/6A or 6A/6A genotype (P = 0.010).

Conclusions: The MMP3 5A/6A promoter polymorphism does not appear to influence breast cancer susceptibility but may be linked to a higher risk for metastasizing among breast cancer patients.

This article has been cited by other articles:

				A. Beeghly-Fadiel, Q. Cai, W. Lu, J. Long, Y.-T. Gao, X.-o. Shu, and W. Zheng No Association between Matrix Metalloproteinase-1 or Matrix Metalloproteinase-3 Polymorphisms and Breast Cancer Susceptibility: A Report from the Shanghai Breast Cancer Study Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1324 - 1327. [Full Text] [PDF]

				J. Zhang, X. Jin, S. Fang, Y. Li, R. Wang, W. Guo, N. Wang, Y. Wang, D. Wen, L. Wei, et al. The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma Carcinogenesis, December 1, 2004; 25(12): 2519 - 2524. [Abstract] [Full Text] [PDF]

				P. Krippl, U. Langsenlehner, W. Renner, H. Koppel, and H. Samonigg Re: Polymorphisms of Death Pathway Genes FAS and FASL in Esophageal Squamous-Cell Carcinoma J Natl Cancer Inst, October 6, 2004; 96(19): 1478 - 1479. [Full Text] [PDF]